Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction

The development of immune checkpoint inhibitors (ICIs) has dramatically altered the landscape of therapy for multiple malignancies, including urothelial carcinoma, non-small cell lung cancer, melanoma and gastric cancer. As part of their anti-tumor properties, ICIs can enhance susceptibility to infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ting, Zhou, Xuyang, Wu, Xingbiao, Zou, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368482/
https://www.ncbi.nlm.nih.gov/pubmed/37497220
http://dx.doi.org/10.3389/fimmu.2023.1207544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368482/
https://www.ncbi.nlm.nih.gov/pubmed/37497220
http://dx.doi.org/10.3389/fimmu.2023.1207544

Ejemplares similares